Categories: News

HEXO Corp. Closes US$144.8 Million Underwritten Public Offering

OTTAWA, Aug. 24, 2021 (GLOBE NEWSWIRE) — HEXO Corp (“HEXO” or the “Company”) (TSX: HEXO; NASDAQ: HEXO) today announced the closing of its previously announced underwritten public offering (the “Offering”) for total gross proceeds to the Company of US$144,786,070.80. The Company sold 49,080,024 units of the Company (the “Units”) at a price of US$2.95 per Unit under the Offering, including 1,622,396 Units sold pursuant to the partial exercise of the underwriters’ over-allotment option.

Each Unit is comprised of one common share of the Company and one half of one common share purchase warrant of the Company. Each full warrant is exercisable to acquire one common share of the Company for a period of 5 years following the closing date of the Offering at an exercise price of US$3.45 per share, subject to adjustment in certain events.

A.G.P./Alliance Global Partners and Cantor Fitzgerald Canada Corporation acted as joint bookrunners for the Offering. ATB Capital Markets Inc. acted as co-manager for the Offering.

The Company expects to use the net proceeds from the Offering to satisfy a portion of the cash component of the purchase price payable to the Redecan shareholders on closing of the Redecan acquisition and for expenditures in relation to the Company’s U.S. expansion plans.

In connection with the Offering, the Company filed a prospectus supplement dated August 20, 2021 (the “Prospectus Supplement”) to the Company’s amended and restated short form base shelf prospectus dated May 25, 2021 (the “Base Shelf Prospectus”) with the securities commissions or similar securities regulatory authorities in each of the provinces and territories of Canada, and with the U.S. Securities and Exchange Commission as part of the Company’s registration statement on Form F-10 (the “Registration Statement”) under the U.S./Canada Multijurisdictional Disclosure System.

Copies of the Prospectus Supplement and the Base Shelf Prospectus are available on SEDAR at www.sedar.com and on EDGAR at www.sec.gov and a copy of the Registration Statement is available on EDGAR at www.sec.gov. Copies of the Prospectus Supplement, the Base Shelf Prospectus and the Registration Statement may also be obtained from A.G.P./Alliance Global Partners, 590 Madison Avenue, 28th Floor, New York, NY 10022, or by telephone at (212) 624-2060, or by email at prospectus@allianceg.com. Copies may also be obtained, from Cantor Fitzgerald Canada Corporation in Canada, by emailing ecmcanada@cantor.com, or Cantor Fitzgerald & Co. in the U.S., by emailing prospectus@cantor.com.

No securities regulatory authority has either approved or disapproved of the contents of this press release. This press release is for information purposes only and shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About HEXO Corp (TSX: HEXO; NASDAQ: HEXO)

HEXO is an award-winning licensed producer of innovative products for the global cannabis market. HEXO serves the Canadian recreational market with a brand portfolio including HEXO, UP Cannabis, Original Stash, Bake Sale, Namaste, and REUP brands, and the medical market in Canada, Israel and Malta. The Company also serves the Colorado market through its Powered by HEXO® strategy and Truss CBD USA, a joint venture with Molson Coors. In the event that the previously announced transactions to acquire 48North and Redecan close, HEXO expects to be the number one cannabis products company in Canada by recreational market share.

Forward Looking Statements

This press release contains forward-looking information and forward-looking statements within the meaning of applicable securities laws (“forward-looking statements”), including statements regarding the use of proceeds from the Offering and the Company’s expectations regarding its market share. Forward-looking statements are based on certain expectations and assumptions and are subject to known and unknown risks and uncertainties and other factors that could cause actual events, results, performance and achievements to differ materially from those anticipated in these forward-looking statements, including that the Company’s use of proceeds of the Offering may differ from those indicated. Forward-looking statements should not be read as guarantees of future performance or results.

A more complete discussion of the risks and uncertainties facing the Company appears in the Prospectus Supplement, the Base Shelf Prospectus and the Registration Statement and in the Company’s Annual Information Form and other continuous disclosure filings, which are available on SEDAR at www.sedar.com and EDGAR at www.sec.gov. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The Company disclaims any intention or obligation, except to the extent required by law, to update or revise any forward-looking statements as a result of new information or future events, or for any other reason.


Investor Relations:

invest@HEXO.com

www.hexocorp.com


Media Relations:

(819) 317-0526

media@hexo.com

 

Staff

Recent Posts

Elation Health Announces Partner Wins; Adds New COO and President

Signaling positive momentum for healthcare technology as the primary care-focused company celebrates 2024 and supporting…

17 minutes ago

Talkiatry Named #6 on 2024 CB Insights’ 50 Most Innovative Digital Health Startups

Talkiatry recognized for achievements in behavioral health care NEW YORK, Dec. 30, 2024 /PRNewswire/ --…

21 minutes ago

Waystar Announces Amendment to Its Credit Facilities

Enhancements expected to boost flexibility and lower borrowing costs LEHI, Utah and LOUISVILLE, Ky., Dec.…

21 minutes ago

ZetrOZ System’s sam(R) Ultrasound Treatment Helps Top Triathlete Return to the Boston Marathon

Former triathlon champ Claudia McCoy used the breakthrough wearable ultrasound unit to boost her recovery…

3 hours ago

Coro Medical Prepares to Roll Out Project AED365 Nationwide Donation Initiative

Project AED365 Aims to Empower Communities, Youth Organizations, First Responders, and more by Providing Lifesaving Automated…

6 hours ago

NLS Pharmaceutics Ltd. and Kadimastem Ltd. Announce Filing of F-4 Registration Statement with the SEC Ahead of Proposed Merger

The proposed transaction will create a Nasdaq-traded, biotechnology company with product candidates in advanced stages…

6 hours ago